Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel

Cancer Treatment Reviews

Volumn 37, Issue 2, 2011, Pages 97-104

  Ortmann, O ^a   Pagani, O ^b   Jones, A ^c   Maass, N ^d   Noss, D ^a   Rugo, H ^e   van de Velde, C ^f   Aapro, Matti ^g   Coleman, R ^h  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g CLINIQUE DE GENOLIER   (Switzerland)

^h WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Adjuvant therapy; Aromatase inhibitors; Breast cancer; Menopause; Perimenopause; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTRADIOL; EXEMESTANE; FOLLITROPIN; GONADOTROPIN; LETROZOLE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; AMENORRHEA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLIMACTERIUM; EARLY CANCER; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INTRADUCTAL CARCINOMA; POSTMENOPAUSE; REVIEW;

ADULT; AMENORRHEA; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PERIMENOPAUSE; TAMOXIFEN;

EID: 79151479122     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.05.005     Document Type: Review

References (44)

1. [accessed 02.03.09]. http://seer.cancer.gov/statfacts/html/breast.html.
2. Tish Knobf M. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. The Oncologist 2006, 11:96-110.
3. [accessed 08.09.09]. http://www.eurohealth.ie/newrep/trends.htm.
4. Ganz P.A., Greendale G.A., Petersen L., et al. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol 2003, 21:4184-4193.
5. Goldhirsch A., Ingle J.N., Gelber R.D., et al. Thresholds for therapies: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329.
6. Goodwin P.J. Options for preservation of fertility in women. N Engl J Med 2005, 353:1418-1420.
7. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366:455-462.
8. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369:559-570.
9. Letrozole therapy alone or in sequence with tamoxifen. N Engl J Med 2009, 361:766-776. The BIG-1 98 Collaborative Group.
10. Regan M.M., Pagani O., Walley B., et al. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. Ann Oncol 2008, 19:1231-1241.
11. Peto R et al. Early Breast Cancer Trialists' Collaborative Group. The worldwide overview: new results for systemic adjuvant therapies. San Antonio breast cancer symposium; 2007. p. A5.
12. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757. Breast International Group (BIG) 1-98 Collaborative Group.
13. Ingle JN, Dowsett M, Cuzick J, Davies C. Aromatase inhibitors vs. tamoxifen for postmenopausal women with ER positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. San Antonio breast cancer symposium; 2008 [Abs. 12].
14. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone-receptor positive breast cancer: status report 2004. J Clin Oncol 2005, 23:619-629.
15. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
16. Faddy M.J., Gosden R.G. A mathematical model of follicle dynamics in the human ovary. Hum Reprod 1995, 10:770-775.
17. Randolph J.F., Crawford S., Dennerstein L., et al. The value of follicle-stimulating hormone concentration and clinical findings as markers of the late menopausal transition. J Clin Endocrin Metab 2006, 91:3034-3040.
18. Burger H.G., Hale G.E., Robertson D.M., et al. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's midlife health project. Hum Reprod Update 2007, 13:559-565.
19. Sowers M.R., Zheng H., McConnell D., et al. Oestradiol rates of change in relation to the final menstrual period in a population-based cohort of women. J Clin Endocrin Metab 2008, 93:3847-3852.
20. Soules M.R., Sherman S., Parrott E., Rebar R., Santoro N., Utian W., et al. Stages of reproductive aging workshop (STRAW). J Women's Health Gend Based Med 2001, 10:843-848.
21. Gracia C.R., Sammel M.D., Freeman E.W., Lin H., Langan E., Kapoor S., et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. Menopause 2005, 12:128-135.
22. Prior J.C. Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation. Endocrine 2005, 26:297-300.
23. Welt C.K., Jimenez Y., Sluss P.M., et al. Control of estradiol secretion in reproductive ageing. Hum Reprod 2006, 21:2189-2193.
24. Sowers M.R., Eyvazzadeh A.D., McConnell D., et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008, 93:3478-3483.
25. Breast cancer. NCCN practice guidelines in oncology v.2.; 2010.
26. Walshe J.M., Denduluri N., Swain S.M. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006, 24:5769-5779.
27. Swain SM, Jeong J-H, Geyer CE, et al. NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. San Antonio breast cancer symposium; 2008 [Abs. 75].
28. Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility. 6th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 1999.
29. Shapiro C.L., Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001, 344:1997-2008.
30. Davis A.L., Klitus M., Mintzer D.M. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of addition of taxanes. Clin Breast Cancer 2005, 6:421-424.
31. Fornier M.N., Modi S., Panageas K.S., et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma aged 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005, 104:1575-1579.
32. Tham Y.L., Sexton K., Weiss H., et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007, 30:126-132.
33. Di Cosimo S., Alimonti A., Ferretti G., et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Ancol 2004, 15:1065-1071.
34. Smith I.E., Dowsett M., Yap Y.-S. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006, 24:2444-2447.
35. Hargis J.B., Nakajima S.T. Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors. Cancer Invest 2006, 24:174-177.
36. Requena A., Herrero J., Landeras J., et al. Use of letrozole in assisted reproduction: a systematic review and meta-analysis. Hum Reprod Update 2008, 14:571-582.
37. Mourits M.J., de Vries E.G., Willemse P.H., et al. Ovarian cysts in women receiving tamoxifen for breast cancer. Br J Cancer 1999, 79:1761-1764.
38. Mourits M.J., de Vries E.G., ten Hoor K.A., et al. Beware of amenorrhea during tamoxifen: it may be a wolf in sheep's clothing. J Clin Oncol 2007, 25:3787-3788.
39. Ravdin P.M., Fritz N.F., Tormey D.C., Jordan V.C. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 1988, 48:1021-1026.
40. Goss PE, Ingle JN, Martino S, et al. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 trial. Cancer Res 2009;69S [Abs. 13].
41. Jannuzzo M.G., Di Salle E., Spinelli R., et al. Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Res Treat 2009, 113:491-499.
42. Rossi E., Morabito A., De Maio E., et al. Endocrine effects of adjuvant letrozole+triptorelin compared with tamoxifen+triptorelin in premenopausal patients with early breast cancer. J Clin Oncol 2008, 26:264-270.
43. Reid D.M., Doughty J., Eastell R., et al. Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK expert group. Cancer Treatment Rev 2008, 34(Suppl. 1):S3-S18.
44. Hadji P., Body J.-J., Aapro M.S., et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008, 19:1407-1416.